| ViroForce Systems Inc. has developed an innovative
and cost-effective solution to the growing and costly problem of disinfecting
rooms in cruise ships, long-term health care facilities, hospitals,
medical clinics, hotels and other spaces susceptible to the numerous
devastating viruses and bacteria that are becoming a daily global
occurrence. Laboratory and in-field tests (third-party test - MRSA
and Norovirus to date) have proven that ViroForce can effectively
disinfect and eradicate: Calicivirus, Norovirus, Corona Virus, Influenza
Virus, H1N1, Rhinovirus, Poliovirus, Herpes Simplex Virus, C. Difficile
and MRSA (Methicillin-resistant Staphylococcus Aureus) and numerous
other bacteria and fungi.
Eliminates Viruses and Bacteria
ViroForce has demonstrated in laboratory experiments that it can
kill more than 99.9% of each of the following viruses:
- Calicivirus (feline strain, a relative of the Norovirus)
- Norovirus
- Corona virus (mouse strain, a relative of the SARS virus)
- Influenza virus (related to H1N1)
- Rhinovirus (common cold virus)
- Poliovirus
- Herpes Simplex virus
ViroForce Systems has also demonstrated the technology is effective
against C. difficile and MRSA (Methicillin-resistant staphylococcus
Aureus) and numerous other bacteria and fungi.
It can also be used in disinfecting against the H5N1 Avian flu, should
it mutate to create a human flu pandemic.
Problems in Hospitals
The cost to hospitals alone in North America and the United Kingdom is more than US$21B per annum.
| Country |
No. of Hospitals. |
Annual Cost US$ |
United States |
5,200 |
$ 12.37 B |
Canada |
1,200 |
$ 2.80 B |
United Kingdom |
2,500 |
$ 5.95 B |
TOTAL COST |
|
$ 21.12 B |
If the ViroForce technology were implemented, it
is anticipated savings would be over US$9.3B per annum. The company
has received written notification from the US FDA that registration
for the sale of the product into the US health care industry is
not required. |